Needham analyst Mike Cikos maintains N-able (NYSE:NABL) with a Buy and raises the price target from $11 to $12.
C4 Therapeutics Q3 EPS $(0.51) Beats $(0.59) Estimate, Sales $8.50M Beat $7.61M Estimate
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 97.09 percent increase over losses of $(17.55) per share from
